32 F. Supp. 3d 538
E.D. Pa.2014Background
- Travelers (workers’ compensation insurers) sued Cephalon and Teva entities, alleging Cephalon fraudulently marketed fentanyl-based drugs Actiq and Fentora for off‑label, non–opioid‑tolerant/non‑cancer uses, causing Travelers to pay for inappropriate, unsafe, or ineffective prescriptions.
- Actiq and Fentora carried FDA‑approved indications limited to opioid‑tolerant cancer patients and prominent warnings (including a Black Box for Fentora); FDA imposed a Risk Management Program and sent advisory communications concerning off‑label risks.
- Plaintiffs allege wide‑ranging promotional tactics: misleading marketing materials, sales rep training, speaker payments, samples/coupons, and targeted promotion to doctors treating workers’ compensation patients who were likely to get full reimbursement.
- Plaintiffs claim at least $15 million paid for Actiq and $4.5 million for Fentora prescriptions and identify a small number of individual prescriptions and several doctors who received payments/benefits; they do not allege direct reliance by plaintiffs on specific misstatements.
- Defendants moved to dismiss for lack of Article III standing (Rule 12(b)(1)) and for failure to state claims (Rule 12(b)(6)), including pleading fraud with particularity (Rule 9(b)). The court granted the motion and dismissed the amended complaint in full.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Article III standing — injury in fact | Travelers paid for drugs that were ineffective/unsafe or more expensive due to Cephalon’s off‑label fraud | Travelers failed to allege a concrete, particularized injury: no allegation that drugs were ineffective for their claimants or caused economic loss | Dismissed for lack of standing; speculative risks and higher price alone insufficient without proof of loss or reduced value |
| Pleading fraud/negligent misrepresentation | Cephalon engaged in an intentional, deceptive marketing campaign over many years aimed at prescribers and TPPs | Allegations are conclusory and fail to identify who said what, when, where, to whom, or any specific false statements or omissions | Dismissed under Rule 9(b) (and Rule 8): off‑label promotion not inherently fraudulent absent specific deceptive statements |
| State consumer protection claims (ascertainable loss/causation) | Travelers may sue under multiple states’ laws because its insureds nationwide filled prescriptions | Travelers did not plead which state laws apply, where prescriptions were filled, or ascertainable loss attributable to defendant communications | Dismissed: plaintiffs failed to plead ascertainable loss, causation, or reliance required by state laws |
| Unjust enrichment / mandatory injunction | Defendants were unjustly enriched by retaining payments for prescriptions; injunction needed to correct prescribing misperceptions | No underlying fraud or demonstrable injury; plaintiffs received some value; injunction is relief not a standalone claim and plaintiffs failed to allege irreparable harm | Dismissed: unjust enrichment not supported; injunction claim fails for lack of irreparable injury and as improperly pleaded |
Key Cases Cited
- Lujan v. Defenders of Wildlife, 504 U.S. 555 (1992) (Article III standing requirements: injury in fact, causation, redressability)
- Bell Atl. Corp. v. Twombly, 550 U.S. 544 (2007) (complaint must plead factual content plausibly suggesting entitlement to relief)
- Ashcroft v. Iqbal, 556 U.S. 662 (2009) (courts disregard conclusory allegations; plausibility standard)
- In re Schering‑Plough Corp. Intron/Temodar Consumer Class Action, 678 F.3d 235 (3d Cir. 2012) (discussing off‑label promotion, FDA regulation, and limits on private FDCA‑based claims)
- In re Neurontin Marketing & Sales Practices Litig. (Kaiser), 712 F.3d 21 (1st Cir. 2013) (TPP may prove economic injury by establishing lack of efficacy for off‑label uses where evidence supports ineffectiveness)
- United States v. Caronia, 576 F. Supp. 2d 385 (E.D.N.Y. 2008) (context on off‑label speech and physician audience; cautions about treating promotional speech to doctors as inherently misleading)